GlassScriptPhysician profile
Zebi Naz
NPI 1114128501
$2,182.86
in general payments reported to CMS, 2019-2025
36 companies · $14.99 in 2025
The $14.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $80.68 · 2022: $74.88 · 2023: $657 · 2024: $848 · 2025: $14.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $242.76 | 2019-2024 | Wegovy, Ozempic |
| Pfizer INC. | $170.11 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.13 | 2019-2024 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $129.21 | 2019-2024 | Gardasil 9, Vaxelis, Proquad |
| Novartis Pharmaceuticals Corporation | $117.53 | 2023-2025 | |
| Amgen INC. | $109.72 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbvie INC. | $107.19 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $100.92 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $83.31 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $80.64 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $78.58 | 2023-2024 | Rexulti |
| Dexcom, INC. | $69.80 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $67.68 | 2023-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $64.93 | 2019 | |
| Exact Sciences Corporation | $56.13 | 2023-2024 | Cologuard Collection Kit |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zebi Naz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.